Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

Contributed by: ACCESS Newswire

Logo

Tags

Healthcare & Pharmaceutical

Ripple Therapeutics

Company Update

More Like This

AviadoBio and UgeneX Therapeutics Announce Exclusive Option-License Agreement to Develop Next Generation Optogenetics Gene Therapy to Restore Vision in Patients with Retinal Disease

Institute of Molecular and Clinical Ophthalmology Basel Spinout RhyGaze Closes USD 86 Million Series A Round to Further Novel Gene Therapy for Vision Restoration

PR Newswire associated0

Daewoong Therapeutics Gets MFDS Nod for Phase 1 IND for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema

PR Newswire associated0

Amacathera Collaborates With Leading Global Pharmaceutical Company To Develop Single-Injection, Long-Acting Biologic Using Its Advanced Hydrogel Delivery Platform, Amacagel™

Vertex Announces Key Advancements Across Kidney Portfolio

VisiRose Introduces Revolutionary Therapy for Severe Eye Infections

Beacon Therapeutics Announces EURETINA 2025 Presentations on 9+-Month Phase 2 DAWN and 36-Month Phase 2 SKYLINE Trial Data for laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP)

Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins